top of page
Suche
  • ODI Pharma

ODI Pharma AB appoints Pareto Securities AB as liquidity provider

ODI Pharma AB (“ODI Pharma” or the “Company”) has today appointed Pareto Securities as the liquidity guarantor for the Company's shares, which are listed for trading on the Spotlight Stock Market. The purpose of the liquidity guarantee is to improve the liquidity of the stock and to reduce the difference between the buying and selling price. The assignment will begin on 19 January 2024.

 

A liquidity provider is an entity that undertakes to promote the trading of a share by ensuring that there are always buy and sell orders in the order book. Pareto Securities, in its role as liquidity provider, will ensure the possibility of trading the Company's shares every day by continuously placing trading posts on both the buy and sell side. A liquidity provider is intended to create a more accurate price picture of a company's stock, leading to a fairer valuation of the company and the possibility of improved trading volume in the stock.

 

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB

E-mail: info@odipharma.com  

 

 

 

 

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.

0 Kommentare

Aktuelle Beiträge

Alle ansehen

ODI Pharma AB: Publication of interim report Q3 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 - March 2024. The report is available as an attached document to this press release and on the Compa

ODI Pharma AB: Updated market and business overview

ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the cannabis industry, particularly in Europe. Progress in the cooper

Comments


bottom of page